Chugai Deploys Phylo's Biomni Lab Agents Across Drug Discovery

Agentic AI is moving from research demos into named pharmaceutical workflows. On August 4, 2026, Phylo announced that Chugai Pharmaceutical will deploy Biomni Lab — Phylo's integrated agentic biology platform — across drug discovery operations, from single-cell analysis to target evaluation.

The deal places one of Japan's most established biopharma innovators among Phylo's founding enterprise customers and extends a rapid sequence of Japanese pharma adoptions for agentic discovery tools.

What Biomni Lab is

Phylo describes Biomni Lab as an Integrated Biology Environment: a workspace that connects AI agents with hundreds of biomedical databases, software tools, and analytical resources. Agents operate on proprietary research data inside a customer's secure perimeter — a requirement for any pharma deployment at scale.

The platform evolved from Biomni, an open-source biomedical agent project originating at Stanford in 2024. Phylo launched commercially in February 2026 with Biomni Lab in research preview, reporting adoption across thousands of research labs and organizations.

Where Chugai will use it

Chugai said Biomni Lab will support multiple discovery areas:

• Single-cell analysis
• Human genetics
• Disease biology
• Target evaluation

These sit on the preclinical side of the pipeline, where scientists make program-defining decisions long before clinical trials. Phylo and Chugai frame the goal as shorter discovery timelines and improved probability of success — standard biopharma metrics, now explicitly tied to agentic tooling.

Quotes from the announcement

Sohei Okamoto of Chugai's Biological Technology Department said the company believes Biomni Lab can help scientists "explore scientific questions more deeply and accelerate drug discovery to create innovative medicines for patients."

Phylo CEO Kexin Huang emphasized prior usage: Chugai scientists were among Biomni's earliest users after the open-source release.

"Our vision is to help biopharma become AI-native, and Biomni Lab is built to make that transition practical for discovery teams today."

A pattern in Japanese pharma

Chugai's adoption follows a July 28, 2026 Ono Pharmaceutical deployment of Biomni Lab — making two major Japanese drugmakers public customers within roughly a week.

Chugai, a Roche Group member listed on Tokyo's Prime Market, brings additional weight: a long R&D track record and global reach through Roche's network.

Why agentic biology is different from chatbots

Discovery scientists routinely stitch together dozens of tools — genomics browsers, pathway databases, statistical packages, internal ELN systems. Agentic platforms promise to orchestrate those steps, generate hypotheses, and document rationale in one environment.

The open question is operational: do agents reduce time-to-decision in target committees, or mainly accelerate individual analyst tasks? Chugai's deployment will be watched for answers.

Risks and realities

Enterprise biology agents must handle hallucination risk, data governance, and validation expectations that exceed consumer AI norms. Phylo's pitch — secure integration with proprietary data — addresses only part of that burden; pharma teams still own experimental validation.

Still, August 2026 marks a clear inflection: agentic AI in drug discovery is graduating from pilot curiosity to named, multi-workflow enterprise rollouts.

Sources

• Phylo, "Phylo and Chugai partner to advance AI agents in drug discovery" (Aug. 4, 2026): https://phylo.bio/blog/chugai-partnership
• PR Newswire release (Aug. 4, 2026): https://www.prnewswire.com/news-releases/phylo-and-chugai-partner-to-advance-ai-agents-in-drug-discovery-302841836.html